Crinetics Pharmaceuticals (CRNX) Stock

A new nonpeptide drug conjugate platform will be introduced, showcasing the preclinical results of its main candidate, CRN09682, which targets tumors that express SST2. This candidate is expected to be submitted for IND approval in early 2025.

A new nonpeptide drug conjugate platform will be introduced, showcasing the preclinical results of its main candidate, CRN09682, which targets tumors that express SST2. This candidate is expected to be submitted for IND approval in early 2025.

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a company in the clinical stage that focuses on creating new treatments for endocrine diseases and related tumors, has announced a public offering of 10,000,000 shares of its common stock at $50.00 each. All shares will be sold by Crinetics, and they expect to raise $500 million before expenses. Additionally, the underwriters have a 30-day option to buy up to 1,500,000 more shares, with the offering expected to close around October 10, 2024, pending standard conditions.

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a company in the clinical stage that focuses on creating new treatments for endocrine diseases and related tumors, announced its plan to sell $400 million worth of its common stock in a public offering, depending on market conditions. Additionally, Crinetics plans to give the underwriters a 30-day option to buy up to $60 million more in shares. However, there is no guarantee about when the offering will be completed or the final details of the offering.

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a company in the clinical stage that works on new treatments for endocrine diseases and related tumors, has announced that its management will take part in discussions at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference, both taking place in New York, NY in September.

Crinetics Pharmaceuticals, Inc. (CRNX) reported a quarterly loss of $0.94 per share, which is worse than the Zacks Consensus Estimate of a $0.86 loss. This is the same loss of $0.94 per share that the company had a year earlier.

Crinetics Pharmaceuticals (CRNX) lacks the necessary elements that could lead to a strong earnings report in the near future. Be ready for the important expectations.

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET that day to discuss financial results and provide a business update.

Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives